Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021;20:385–97.

PubMed  PubMed Central  Google Scholar 

GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939–53.

Google Scholar 

Abou-Sleiman PM, Muqit MMK, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci. 2006;7:207–19.

PubMed  Google Scholar 

Kouli A, Torsney KM, Kuan W-L. Parkinson’s disease: etiology, neuropathology, and pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson’s disease: pathogenesis and clinical aspects. Brisbane: Codon Publications; 2018.

Google Scholar 

Dai C, Tan C, Zhao L, Liang Y, Liu G, Liu H, Zhong Y, Liu Z, Mo L, Liu X, Chen L. Glucose metabolism impairment in Parkinson’s disease. Brain Res Bull. 2023;199: 110672.

PubMed  Google Scholar 

Hong C-T, Chen K-Y, Wang W, Chiu J-Y, Wu D, Chao T-Y, Hu C-J, Chau K-YD, Bamodu OA. Insulin resistance promotes Parkinson’s disease through aberrant expression of α-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling. Cells. 2020. https://doi.org/10.3390/cells9030740.

PubMed  PubMed Central  Google Scholar 

Wang R, Shih LC. Parkinson’s disease - current treatment. Curr Opin Neurol. 2023;36:302–8.

PubMed  Google Scholar 

Cullinane PW, de Pablo Fernandez E, König A, Outeiro TF, Jaunmuktane Z, Warner TT. Type 2 diabetes and parkinson’s disease: a focused review of current concepts. Mov Disord. 2023;38:162–77.

PubMed  Google Scholar 

Svenningsson P, Wirdefeldt K, Yin L, Fang F, Markaki I, Efendic S, Ludvigsson JF. Reduced incidence of Parkinson’s disease after dipeptidyl peptidase-4 inhibitors-a nationwide case-control study. Mov Disord. 2016;31:1422–3.

PubMed  Google Scholar 

Michailidis M, Moraitou D, Tata DA, Kalinderi K, Papamitsou T, Papaliagkas V. Alzheimer’s disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer’s disease and type 2 diabetes. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23052687.

PubMed  PubMed Central  Google Scholar 

Zhang Y, Chen Y, Li L, Hölscher C. Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson’s disease mouse model. Behav Brain Res. 2015;293:107–13.

PubMed  Google Scholar 

Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease. J Neuroinflammation. 2008;5:19.

PubMed  PubMed Central  Google Scholar 

Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel J-C, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Aβ oligomers. J Clin Invest. 2012;122:1339–53.

PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88: 105906.

PubMed  Google Scholar 

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane; 2024.

Hogg E, Wu T, Bresee C, Wertheimer J, Malatt C, Tan E, Pomeroy H, Nuno M, Wyse R & Tagliati M. A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson’s Disease. SSRN Journal; 2022.

Li T, Higgins JPT, Deeks JJ. Chapter 5: Collecting data [last updated October 2019]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane; 2024. cochrane.org/handbook

McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV, Thomas J. Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane; 2024. cochrane.org/handbook.

Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18:738–50.

Google Scholar 

Sjödahl Hammarlund C, Nilsson MH, Hagell P. Measuring outcomes in Parkinson’s disease: a multi-perspective concept mapping study. Qual Life Res. 2012;21:453–63.

PubMed  Google Scholar 

Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Metzendorf M-I, Noel-Storr A, Paynter R, Rader T, Thomas J, Wieland LS. Chapter 4: Searching for and selecting studies [last updated March 2025]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5.1 Cochrane; 2025. cochrane.org/handbook.

Muka T, Glisic M, Milic J, Verhoog S, Bohlius J, Bramer W, Chowdhury R, Franco OH. A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research. Eur J Epidemiol. 2020;35:49–60.

PubMed  Google Scholar 

EndNote - Citation & Reference Management Tool. https://endnote.com/?srsltid=AfmBOoqB-MAtazd1KSYVBrKyYu8mD4vpDWwRnu5cgLBjM45y8rIJKIwM

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.

PubMed  PubMed Central  Google Scholar 

“automeris.io: Computer vision assisted data extraction from charts using WebPlotDigitizer. https://automeris.io/. Accessed 25 Aug 2024.

"Meta-Analysis Accelerator | Your Meta-Analysis Conversion Tool. https://meta-converter.com

Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664–75.

PubMed  PubMed Central  Google Scholar 

Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T. Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest. 2013;123:2730–6.

PubMed  PubMed Central  Google Scholar 

Malatt C, Wu T, Bresee C, Hogg E, Wertheimer J, Tan E, Pomeroy H, Obialisi G, Tagliati M. Liraglutide improves non-motor function and activities of daily living in patients with Parkinson’s disease: a randomized, double-blind, placebo-controlled trial (P9–11.005). Neurology. 2022. https://doi.org/10.1212/WNL.98.18_supplement.3068.

Google Scholar 

McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Kieburtz K. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024;23:37–45.

PubMed  Google Scholar 

Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto J-L, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrière N, Catala H, Colin O, Corvol J-C, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, LIXIPARK Study Group. Trial of lixisenatide in early parkinson’s disease. N Engl J Med. 2024;390:1176–85.

PubMed  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.

PubMed  Google Scholar 

Higgins JPT, Li T, Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane; 2024. cochrane.org/handbook.

Safety and Efficacy of Liraglutide in Parkinson’s Disease. Available at: https://www.clinicaltrials.gov/study/NCT02953665?cond=Parkinson%27s%20Disease&term=glp-1&rank=10

The Cochrane Collaboration. Review Manager (RevMan)[computerprogram]. Version 5.4. 2020. https://login.cochrane.org/realms/cochrane/protocol/openid-connect/auth?client_id=revman-web&redirect_uri=https%3A%2F%2Frevman.cochrane.org&response_type=code&scope=openid%20profile&nonce=8ccf28f5aeff2e02c6dfb482c52de44befKjVOtjQ&state=6d9731f6d393efb414301a963b42ed8ecajw3WtuZ&code_challenge=M3yCEQMDg20WA-gKqE_CUCWqIa8q0ZUC2cMWkx-ucsw&code_challenge_method=S256

Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Skene SS, Chowdhury K, Aviles-Olmos I, Limousin P, Foltynie T. What effects might Exenatide have on non-motor symptoms in Parkinson’s disease: a post hoc analysis. J Parkinsons Dis. 2018;8:247–58.

PubMed  Google Scholar 

Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J Parkinsons Dis. 2014;4:337–44.

PubMed  Google Scholar 

Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Aviles-Olmos I, Chowdhury K, Skene SS, Limousin P, Foltynie T. Post hoc analysis of the Exenatide-PD trial-factors that predict response. Eur J Neurosci. 2019;49:410–21.

PubMed  Google Scholar 

Athauda D, Wyse R, Brundin P, Foltynie T. Is exenatide a treatment for Parkinson’s disease? J Parkinsons Dis. 2017;7:451–8.

PubMed  Google Scholar 

Athauda D, Budnik N, Chowdhury K, Skene S, Foltynie T. The effect of exenatide on specific non-motor symptoms in Parkinson’s disease—a post-hoc analysis. In: European Journal of Neurology. Issue S2 edition. Vol. 25. Abstracts of the 4th congress of the European academy of neurology, Lisbon, Portugal, 2018, 2018:309.

Foltynie T, Aviles-Olmos I. Exenatide as a potential treatment for patients with Parkinson’s disease: first steps into the clinic. Alzheimers Dement. 2014;10:S38-46.

PubMed  Google Scholar 

Aviles-Olmos I, Dickson J, Kefalopoupou Z, Djamshidian A, Kahan J, Ell P, et al. Exenatide and non motor symptoms In Parkinson’s disease (PD) [abstract]. In: Movement Disorders. Vol. 29 Suppl 1 6:12. 2014.

Aviles-Olmos I & Kefalopoulou Z (2012) Aviles-Olmos I, Kefalopoulou Z, Djamshidian A, Limousin P, Dickson J, Lees A, et al. An open label, single site, 12 month, phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (exenatide) in the treatment of patients with moderate severity Parkinson’s disease [abstract]. Movement Disorders 2012;27(Suppl 1:343). Movement ….

Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, et al. Exenatide and motor symptoms in Parkinson’s disease (PD) [abstract]. In: Movement Disorders. Vol. 29 Suppl 1:611; 2014.

Effects of Exenatide on Motor Function and the Brain. ClinicalTrials.gov Identifier: NCT03456687. https://www.clinicaltrials.gov/study/NCT03456687?cond=Parkinson%27s%20Disease&term=glp-1&rank=1

Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson’s Disease (Exenatide-PD3). ClinicalTrials.gov Identifier: NCT04232969. https://clinicaltrials.gov/study/NCT04232969

SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson’s Disease. ClinicalTrials.gov Identifier: NCT04269642. https://clinicaltrials.gov/study/NCT04269642?term=AREA%5BConditionSearch%5D(Neurodegenerative%20Diseases)%20AND%20AREA%5BInterventionSearch%5D(exendin-4)&rank=9

GLP1R in Parkinson’s Disease (GIPD). ClinicalTrials.gov Identifier: NCT03659682. https://clinicaltrials.gov/study/NCT03659682

Exenatide Treatment in Parkinson’s Disease. ClinicalTrials.gov Identifier: NCT04305002. https://clinicaltrials.gov/study/NCT04305002

Murakami H, Shiraishi T, Umehara T, Omoto S, Iguchi Y. Recent advances in drug therapy for Parkinson’s disease. Intern Med. 2023;62:33–42.

PubMed  Google Scholar 

Murata M, Mihara M, Hasegawa K, Jeon B, Tsai C-H, Nishikawa N, Oeda T, Yokoyama M, Robieson WZ, Ryman D, Eaton S, Chatamra K, Benesh J. Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson’s disease patients. NPJ Parkinsons Dis. 2016;2: 16020.

PubMed  PubMed Central  Google Scholar 

Takeda A, Takahashi R, Tsuboi Y, Nomoto M, Maeda T, Nishimura A, Yoshida K, Hattori N. Randomized, controlled study of opicapone in Japanese Parkinson’s patients with motor fluctuations. Mov Disord. 2021;36:415–23.

PubMed  Google Scholar 

Athauda D, Evans J, Wernick A, Virdi G, Choi ML, Lawton M, Vijiaratnam N, Girges C, Ben-Shlomo Y, Ismail K, Morris H, Grosset D, Foltynie T, Gandhi S. The